4.8 Article

Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 160, Issue 2, Pages 254-263

Publisher

ELSEVIER
DOI: 10.1016/j.jconrel.2011.12.038

Keywords

Liposomes; Octreotate; Somatostatin; Positron emission tomography; Targeting ligand; Nanoparticles

Funding

  1. Danish Strategic Research Council (NABIIT) [2106-07-0033]
  2. Technical University of Denmark (DTU)
  3. AP Moller Foundation
  4. Danish National Advanced Technology Foundation
  5. Novo Nordisk Foundation
  6. Lundbeck Foundation

Ask authors/readers for more resources

Targeted therapeutic and diagnostic nanocarriers functionalized with antibodies, peptides or other targeting ligands that recognize over-expressed receptors or antigens on tumor cells have potential in the diagnosis and therapy of cancer. Somatostatin receptors (SSTRs) are over-expressed in a variety of cancers, particularly neuroendocrine tumors (NETs) and can be targeted with somatostatin peptide analogs such as octreotate (TATE). In the present study we investigate liposomes that target SSTR in a NET xenograft mouse model (NCI-H727) by use of TATE. TATE was covalently attached to the distal end of DSPE-PEG(2000) on PEGylated liposomes with an encapsulated positron emitter Cu-64 that can be utilized for positron emission tomography (PET) imaging. The biodistribution and pharmacokinetics of the Cu-64-loaded PEGylated liposomes with and without TATE was investigated and their ability to image NETs was evaluated using PET. Additionally, the liposome accumulation and imaging capability was compared with free radiolabelled TATE peptide administered as Cu-64-DOTA-TATE. The presence of TATE on the liposomes resulted in a significantly faster initial blood clearance in comparison to control-liposomes without TATE. PEGylated liposomes with or without TATE accumulated at significantly higher quantities in NETs (5.1+/-0.3 and 5.8+/-0.2 % ID/g, respectively) than the free peptide Cu-64-DOTA-TATE (1.4+/-0.3 % ID/g) 24 h post-injection. Importantly, Cu-64-loaded PEGylated liposomes with TATE showed significantly higher tumor-to-muscle (T/M) ratio (12.7+/-1.0) than the control-liposomes without TATE (8.9+/-0.9) and the Cu-64-DOTA-TATE free peptide (7.2+/-0.3). The higher T/M ratio of the PEGylated liposomes with TATE suggests some advantage of active targeting of NETs, although no absolute benefit in tumor accumulation over the non-targeted liposomes was observed. Collectively, these data showed that Cu-64-loaded PEGylated liposomes with TATE conjugated to the surface could be promising new imaging agents for visualizing tumor tissue and especially NETs using PET. (C) 2012 Elsevier B. V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available